Trametinib (GSK1120212)

For research use only.

Catalog No.S2673 Synonyms: JTP-74057, Mekinist

904 publications

Trametinib (GSK1120212) Chemical Structure

CAS No. 871700-17-3

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 283 In stock
EUR 117 In stock
EUR 206 In stock
EUR 658 In stock
EUR 1051 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Trametinib (GSK1120212) has been cited by 904 publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.
Features More potent than PD0325901 or AZD6244.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
0.92 nM 1.8 nM
In vitro

GSK1120212 inhibits the phosphorylation of MBP regardless of the isotype of Raf and MEK, with IC50 ranging from 0.92 nM to 3.4 nM. GSK1120212 demonstrates no inhibition of the kinase activities of c-Raf, B-Raf, ERK1 and ERK2. In addition, GSK1120212 does not show drastic inhibitory activity against the other 98 kinases. GSK1120212 displays potent inhibitory activity against human colorectal cancer cell lines. HT-29 and COLO205 cells, which are known to have a constitutively active B-Raf mutant, are most sensitive to GSK1120212 with IC50 0.48 nM and 0.52 nM, respectively. The cell lines bearing a K-Ras mutation show a wide range of sensitivity to GSK1120212 with IC50 of 2.2-174 nM. In contrast, COLO320 DM cells, bearing the wild-type gene in both B-Raf and K-Ras, are found to be resistant to GSK1120212 even at 10 μM. GSK1120212 treatment for 24 hours induces cell-cycle arrest at the G1 phase in all sensitive cell lines. Consistently, GSK1120212 treatment leads to upregulation of p15INK4b and/or p27KIP1 in most of the colorectal cancer cell lines. GSK1120212 inhibits constitutive ERK phosphorylation in all sensitive cell lines. GSK1120212 induces apoptosis both in HT-29 and COLO205 cells, but that COLO205 cells are more sensitive to GSK1120212 than HT-29 cells in terms of apoptosis induction. [1] GSK1120212 blocks tumor necrosis factor-α and interleukin-6 production from peripheral blood mononuclear cells (PBMCs). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231, SW480 and SW1116 cells M{KxbWZ2dmO2aX;uJIF{e2G7 MoHiNVAx6oDLbl2= M2XaW|I1KGh? NX21SWVmfHKjbXX0bY5q[iClb4Xs[EBl\WO{ZXHz[UB[SVBibHX2[Yx{KGGwZDDpcohq[mm2IFzNRk1qdmS3Y3XkJHlCWCC3cILl[5Vt[XSrb36gbY4hVUSDLV3CMVI{OSxiU2exNVE3KGGwZDDTW|Q5OCClZXzsdy=> NWKybo5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C4N|M3PjVpPkOwPFM{PjZ3PD;hQi=>
RG7388-resistant U87MG cells MVTGeY5kfGmxbjDhd5NigQ>? MXexNEBvVQ>? NHrCToszPCCq MmL6SG1UVw>? NVToSoZ{XHKjbXX0bY5q[iC2cnXheI1mdnRicnXkeYNm\CC2aHWgbY53[XOrdnWgdIhmdm:2eYDlJI9nKFKJN{O4PEBz\XOrc4ThcpQh[2WubIOu NIHQTlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK3OFk5PCd-M{CyO|Q6QDR:L3G+
BJAB cells MVXGeY5kfGmxbjDhd5NigQ>? NXP2OpBbOC5yMd88US=> MlfvNlQhcA>? M2jBPFAvODFizszNJJRz[W2ndHnubYIh\W[oZXP0bZZmdHlic4XwdJJme3OnZDD0bIUhTVKNIHj5dIVz[WO2aY\heIlwdiCrbjDCTmFDKGOnbHzzJINifXOnZDDifUB1cGViY3;tZolv\WRidILlZZRu\W62IH;mJGJMVTF{MDDhcoQhTGGwdYPldpRq[i5? NYHz[5hQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5OFc2PzZpPkOwPVQ4PTd4PD;hQi=>
Human PDAC cell lines (MIA-PACA, PANC-1, CFPAC-1, PL45, CAPAN-2 and HPAF-II) MnrjSpVv[3Srb36gZZN{[Xl? MnfONVAhdk1ib4KgNVAxKG6P MUKzMYRigXNib4KgOk1l[Xm| MnTaWIhmKGOxbnPlcpRz[XSrb36gc4YhOTBibl2geJJidWW2aX7pZkBkd26|aYP0[Y51dHlicILv[JVk\WRic3nncolncWOjboSg[Iln\mW{ZX7j[ZMh[mW2d3XlckBo\W[rdHnubYIh[W6mIITyZY1mfGmwaXKgZYxwdmViY3;tdIFz\WRidH:gZ49u[mmwYYTpc44h\2WoaYTpcoljKGGwZDD0doFu\XSrbnniJIlvKGGubDDmc5VzKHOnboPpeIl3\SClZXzsJIxqdmW|IDjDSnBCSy1zLDDwcFQ2NCCFQWDBUk0zKGGwZDDIVGFHNUmLKT6gUo8h[WSmaYTpeoUh\W[oZXP0JJdieyCxYoPldpZm\CCrbjD0bIUh\2WoaYTpcoljKGmwc3Xud4l1cX[nIH;yJIV5[2m2YYTvdpkh[2WubDDsbY5meyBqTVnBMXBi[2FiYX7kJHBCVkNvMTm= MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7MkGzOVEoRjNyOUKxN|UyRC:jPh?=
Transitional cell carcinoma (TCC) cell lines NVv1dVE4TnWwY4Tpc44h[XO|YYm= MV[yOUBvVQ>? NUHQVWJyPi1{NDDo NYXpbpZbS2GwaX7lJHRESyClZXzsJIxqdmW|IHHy[UB{\W6|aYTpeoUhfG9iTVXLJIlvcGmkaYTpc44> NI\TXo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUC0PFU1QCd-M{GwOFg2PDh:L3G+
COLO205 MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mkn2O|IhcA>? NVqxcnF{UUN3MDC9JFAvODBzIN88US=> MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
HT-29 NWDOOoc1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWXzNlBMPzJiaB?= MXvJR|UxKD1iMD6wNFEh|ryP NEXCW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
COLO205 MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTkXXg4OiCq NITqdYpKSzVyIE2gNE4xODFizszN MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
MV522 Mlv6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M333UVczKGh? NEL0bWtKSzVyIE2gNE4xODFizszN NF72dZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
HT-29 MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHf2c5g4OiCq NFW4dIRKSzVyIE2gNE4xODJizszN NGDlV2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
MV522 NEnrTVdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HUOlczKGh? MmT1TWM2OCB;IECuNFAzKM7:TR?= NWDlNmhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
NCI-H727 MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4PqTlczKGh? Mo[2TWM2OCB;IECuNFAzKM7:TR?= Mlv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
NCI-H727 MkHGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NULxV4tkPzJiaB?= MXHJR|UxKD1iMD6wNFIh|ryP MnHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
SW1417 NGfxPHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;VeZhMPzJiaB?= MWTJR|UxKD1iMD6wNFMh|ryP NI\5U3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
SW1417 MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYK3NkBp M33EVWlEPTBiPTCwMlAxOyEQvF2= NGKyc3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
Calu6 NUPNbGhXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHixb3k4OiCq M{HOSGlEPTBiPTCwMlAxOyEQvF2= MnjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
LS1034 NHj3fHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NG\MdZg4OiCq NIrwUFdKSzVyIE2gNE4xODRizszN MnzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
SW1463 M4roSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjkSVM4OiCq M16wcGlEPTBiPTCwMlAxPCEQvF2= M1;afFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
SW1463 M3;KXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3PUe|czKGh? MoHzTWM2OCB;IECuNFA1KM7:TR?= NGraS449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
Calu6 NF;ve3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWi3NkBp NVKxd4NLUUN3MDC9JFAvODB2IN88US=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
LS1034 MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEKwbmo4OiCq MoG1TWM2OCB;IECuNFA2KM7:TR?= M3LGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
RKO NFX2RWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFzJXow4OiCq MoHCTWM2OCB;IECuNFA2KM7:TR?= NWT1VpZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
NCI-H508 M1;CRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGTTU3Q4OiCq MUXJR|UxKD1iMD6wNFgh|ryP NETjNHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
KM12 NVz1PYJnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1\ITlczKGh? NVP3VWVxUUN3MDC9JFAvODFizszN M4PCblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
A427 NV2xRpdPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\GNYFiPzJiaB?= M4PNTGlEPTBiPTCwMlAyKM7:TR?= MkLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
NCI-H1155 MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWTnTZFbPzJiaB?= M2DsbWlEPTBiPTCwMlAyKM7:TR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
HCT8 NX;HdWltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWf6OpZLPzJiaB?= Mn;oTWM2OCB;IECuNFE1KM7:TR?= MlrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
MDA-MB-175-VII NVK3OFc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoXDO|IhcA>? NXHDNYtDUUN3MDC9JFAvODF4IN88US=> M{LI[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
A549 M2X2O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWT1XHBLPzJiaB?= NITwXJZKSzVyIE2gNE4xOTZizszN MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
RKO NFrHcWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmPjO|IhcA>? M1XkeWlEPTBiPTCwMlAyQCEQvF2= MknIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
NCI-H23 NVLnUY1vT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1LvdVczKGh? M2HjbWlEPTBiPTCwMlAzKM7:TR?= NVHtVXZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
A427 NUC1SoxNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWe1PIRCPzJiaB?= M4Pt[GlEPTBiPTCwMlAzOiEQvF2= NYjPZWJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
KM12 NHjLc41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYXHW3c5PzJiaB?= M17nUmlEPTBiPTCwMlAzOyEQvF2= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
NCI-H508 NHm1SmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4LUTFczKGh? M13YbWlEPTBiPTCwMlAzOyEQvF2= M3z5XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
MDA-MB-231 NYXUWmtLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\OUW9MOyCmYYnz MULHTVUxKD1iMD6wNlUh|ryP Mo\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
SW837 MnXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3Sxd|czKGh? M4i5WGlEPTBiPTCwMlAzPSEQvF2= NGf1S489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
SW480 MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3vXJg4OiCq MlHITWM2OCB;IECuNFI3KM7:TR?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
NCI-H1355 NVvseHltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYThXZE1PzJiaB?= MUHJR|UxKD1iMD6wNlch|ryP M4\vUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
NCI-H23 NHTufWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXnrZoR7PzJiaB?= NVuwS5VwUUN3MDC9JFAvODJ7IN88US=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
EFM19 MlXpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mo[xO|IhcA>? Mkm0TWM2OCB;IECuNFMh|ryP NXXvN5E1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
T84 MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\aO|IhcA>? NIi5elJKSzVyIE2gNE4xOyEQvF2= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
A549 M2jRRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoD3O|IhcA>? MU\JR|UxKD1iMD6wN|Qh|ryP NEPjWpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H1792 M{Dlb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWWxO3RjPzJiaB?= NEC5ZnhKSzVyIE2gNE4xOzVizszN MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
SW480 NFHmNXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmPLO|IhcA>? MlO1TWM2OCB;IECuNFM4KM7:TR?= M1;idlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
COR-L23 NFHK[nVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2nHcFczKGh? NYnLflVHUUN3MDC9JFAvODN5IN88US=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
SW1573 NFPEUHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLpR3RIPzJiaB?= MV;JR|UxKD1iMD6wN|gh|ryP NF7KRng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
Calu3 NXHhS5V{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUO3NkBp M{LWdmlEPTBiPTCwMlA{QSEQvF2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
HCC827 NF3WSpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlfIO|IhcA>? MljnTWM2OCB;IECuNFQh|ryP M3Tk[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
HOP62 Mn2zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW[3NkBp MVPJR|UxKD1iMD6wOUDPxE1? MmX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
NCI-H1355 M4D1cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37SeFczKGh? MYLJR|UxKD1iMD6wOVIh|ryP NF3Hd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H1792 NH\pSWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXpfXQ4OiCq NVjFSm1uUUN3MDC9JFAvODV|IN88US=> NXrGW4Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
HCT8 MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;oO|IhcA>? NWXobGR7UUN3MDC9JFAvODV3IN88US=> MlnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
T84 NUL2UGloT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUK3NkBp MYPJR|UxKD1iMD6wOlEh|ryP NVO3RnhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
SW900 NX;vc2Q1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7uO|IhcA>? Mn2zTWM2OCB;IECuNFczKM7:TR?= Mom2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
SW837 NVXIRohVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVm2T2VUPzJiaB?= MlTzTWM2OCB;IECuNFc1KM7:TR?= NWD4cItvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
DLD1 M{O0eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33zTlczKGh? M{LtUGlEPTBiPTCwMlA6OyEQvF2= Mn3LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
MDA-MB-175-VII M2\GSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;GO|IhcA>? MYPJR|UxKD1iMD6wPVYh|ryP Mo\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
SW900 NEfsdVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3XVUVczKGh? MUfJR|UxKD1iMD6xNlch|ryP MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
Calu3 NIHkVGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW[3NkBp NWK0So1iUUN3MDC9JFAvOTV6IN88US=> M2PP[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
COR-L23 NVnVOZRqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWS3NkBp MUHJR|UxKD1iMD6zNlkh|ryP MmPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
DLD1 MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUm3NkBp M2K4ZWlEPTBiPTCwMlY{OiEQvF2= Mk\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ERRα / IDH3 / c-Myc / Cyclin D1; 

PubMed: 30185207     


WB for ERRα, IDH3A, c-Myc and Cyclin D1 in the HCT116 and SW480 cells treated with the indicated concentrations of trametinib (0–100 nM) or DMSO for 48 h. 

pERK /ERK / pS6 / S6 ; 

PubMed: 29133622     


BRAF/NRAS-WT cell lines were treated with vehicle, ceritinib, trametinib or ceritinib-trametinib for 24h before extraction of protein and Western blot for pERK or pS6. Numbers above pS6 indicate the densitometry measurements expressed as a proportion of total S6. 

β-catenin; 

PubMed: 28422736     


The antibodies against phospho-ERK (p-ERK), total ERK (t-ERK) and β-catenin were used to determine the effect of trametinib on the levels of p-ERK and β-catenin in the indicated cells. GAPDH was used as a loading control.

30185207 29133622 28422736
Growth inhibition assay
Cell proliferation; 

PubMed: 30185207     


Cell proliferation was measured using the Cell Counting Kit-8 (CCK-8) assay in the HCT116 and SW480 cells treated with trametinib at 25 nm, 50 nM and 100 nM for 3 d.

MTT assay; 

PubMed: 26832408     


Percent viability of A549 cells determined by MTT assay plotted on a logarithmic molar dose curve scale. Shown are trametinib and fluvastatin single drug dose curves and fluvastatin dose curve with fixed trametinib dosing.

30185207 26832408
Immunofluorescence
phospho-PR(S345); 

PubMed: 29237804     


IF of the nuclear phospho-PR (S345) in ISHIKAWA cells treated with 10 μM onapristone, 100nM trametinib, or a combination for 24 hours.

β-catenin; 

PubMed: 28422736     


Immunofluorescence assay was used to investigate the effect of trametinib on subcellular localization of β-catenin in NOZ and GBC-SD cells. Red color represents nuclear and cytoplasmic staining of β-catenin, and blue color represents Hoeschst 33342 staining for nuclei. Scale bars, 200 μm.

29237804 28422736
In vivo Oral administration of GSK1120212 at 0.3 mg/kg or 1 mg/kg once daily for 14 days is effective in inhibiting the HT-29 xenograft growth, and 1 mg/kg of GSK1120212 almost completely blocks the tumor increase. The phosphorylation of ERK1/2 is completely inhibited in the established tumor tissues by single oral dose of 1 mg/kg GSK1120212, and both p15INK4b and p27KIP1 protein levels are upregulated after 14 days of treatment with GSK1120212. In the COLO205 xenograft model, tumor regression is observed even at a dose of 0.3 mg/kg. At a dose of 1 mg/kg, a complete regression is obtained in 4 out of 6 mice in which the tumor degenerates to the point that tumor volume is not measurable. [1] Administration of GSK1120212 at 0.1 mg/kg almost completely suppresses adjuvant-induced arthritis (AIA) and type II collagen-induced arthritis (CIA) in Lewis rats or DBA1/J mice, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Raf-MEK-ERK cascade kinase assay:

Non-phosphorylated myelin basic protein (MBP) is coated onto an ELISA plate, and the active form of B-Raf/c-Raf is mixed with unphosphorylated MEK1/MEK2 and ERERK2 in 10 μM ATP and 12.5 mM MgCl2 containing MOPS buffer in the presence of various concentrations of GSK1120212. The phosphorylation of MBP is detected by the anti-phospho-MBP antibody.
Cell Research:[1]
- Collapse
  • Cell lines: HT-29, HCT-15, HCT116, COLO205, LS-174T, SW480, SW620, T84, LoVo and COLO320
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 3 or 4 days
  • Method: Exponentially growing cells are precultured in 96-well tissue culture plates for 24 hours and then exposed to GSK1120212. Cell growth is determined by an in vitro toxicology assay kit, sulforhodamine B based. For apoptosis assay, both floating and adherent cells are collected and fixed with 70% ethanol. After washing with PBS, the cells are suspended in 100 μg/mL RNase and 25 μg/mL propidium iodide (PI) and incubated at 37 °C for 30 minutes in the dark. The DNA content of each single cell is determined using the flow cytometer Cytomics FC500 or Guava EasyCyte plus.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female BALB/c-nu/nu mice inoculated subcutaneously with HT-29 or COLO205 cells
  • Dosages: ~1 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 22 mg/mL warmed (35.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+corn oil
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 615.39
Formula

C26H23FIN5O4

CAS No. 871700-17-3
Storage powder
in solvent
Synonyms JTP-74057, Mekinist
Smiles CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04547946 Not yet recruiting Drug: dabrafenib + trametinib Malignant Melanoma Novartis Pharmaceuticals|Novartis January 29 2021 --
NCT04566133 Not yet recruiting Drug: Trametinib|Drug: Hydroxychloroquine Bile Duct Cancer|Biliary Cancer|Biliary Tract Neoplasms|Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 5 2021 Phase 2
NCT04454476 Not yet recruiting Drug: Trametinib treatment|Procedure: Endoscopy Gastric Cancer|Metaplasia|Stage I Gastric Cancer|Initial-onset Gastric Cancer Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) January 2021 Phase 1
NCT04485559 Recruiting Drug: Everolimus|Drug: Trametinib Recurrent World Health Organization (WHO) Grade II Glioma University of California San Francisco|Novartis Pharmaceuticals|Pediatric Brain Tumor Foundation|The Lilabean Foundation for Pediatric Brain Cancer Research December 9 2020 Phase 1
NCT04666272 Not yet recruiting Drug: dabrafenib|Drug: trametinib Melanoma Novartis Pharmaceuticals|Novartis December 22 2020 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you help us with the best way to prepare Trametinib for in vivo i.p. injections?

  • Answer:

    S2673 can be dissovled in 4% DMSO/corn oil at 3 mg/ml clearly.

  • Question 2:

    How to solve the problem that this product didn't dissolve up to 10mM in DMSO at room temperature?

  • Answer:

    The solution can be heated up to 50 degree to help dissolve. Besides, sonication (with a probe sonicator) also helped greatly.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy Trametinib (GSK1120212) | Trametinib (GSK1120212) supplier | purchase Trametinib (GSK1120212) | Trametinib (GSK1120212) cost | Trametinib (GSK1120212) manufacturer | order Trametinib (GSK1120212) | Trametinib (GSK1120212) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID